Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $50.00

Oruka Therapeutics (NASDAQ:ORKA) had its target price boosted by equities researchers at Barclays from $48.00 to $50.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential upside of 25.41% from the stock’s current price.

Several other analysts also recently issued reports on ORKA. UBS Group assumed coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Piper Sandler assumed coverage on Oruka Therapeutics in a research report on Thursday, December 18th. They set an “overweight” rating and a $75.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Stifel Nicolaus raised their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday. Finally, BTIG Research reissued a “buy” rating and issued a $73.00 price target on shares of Oruka Therapeutics in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $56.67.

Oruka Therapeutics Stock Performance

ORKA stock traded up $7.88 during midday trading on Friday, hitting $39.87. 1,460,790 shares of the stock were exchanged, compared to its average volume of 440,491. The stock’s 50-day moving average price is $32.68 and its 200-day moving average price is $27.32. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -20.98 and a beta of -0.38. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $41.19.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.16. Research analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares of the company’s stock, valued at $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 21,000 shares of company stock valued at $663,530 over the last ninety days. 24.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its position in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Kennedy Capital Management LLC raised its position in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after purchasing an additional 788 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after buying an additional 904 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: BTIG reiterated a “buy” rating and raised its price target to $73 (≈84.6% upside vs. $39.54), signaling strong commercial comparables for ORKA‑001 that support a materially higher valuation. BTIG reiterates buy on Oruka
• Positive Sentiment: Stifel Nicolaus raised its price target to $72 and kept a “buy” call (≈82% upside), adding another institutional endorsement that likely amplified buying interest. Stifel raises PT to $72
• Positive Sentiment: Guggenheim reaffirmed a “buy” and a $60 target (~52% upside), while Wedbush maintained an “outperform” with a $45 target (~14% upside) — multiple firms pointing to upside helps validate the story for momentum traders and long-only investors. Guggenheim & Wedbush notes
• Positive Sentiment: Oruka reported Q4 results: EPS of ($0.45) beat consensus of ($0.61), showing better-than-expected financial performance and relieving some near-term execution risk. Quarterly results and press release
• Positive Sentiment: Corporate update: ORKA‑001 EVERLAST‑A 16‑week data are now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — faster enrollment reduces timeline risk and makes near-term clinical catalysts clearer. Corporate update / GlobeNewswire

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.